Robert N. Sahr, PhD
Shareholder
| Biotechnology
Overview
Rob Sahr develops strategies for life science companies to maximize exclusivity for therapeutic and diagnostic products. Rob assists clients with building global patent portfolios aligned with product life cycle, and advises clients on regulatory exclusivities, patent term extensions, Orange Book listings, and biosimilars.
In addition to pharma and biotech companies, Rob works with universities, research institutions, and venture capital investors, providing patentability and freedom-to-operate assessments, non-infringement and invalidity opinions, performing IP diligence, and preparing agreements.
Rob has also assisted federal grant recipients and contractors with Bayh-Dole compliance, including use of iEdison.
Rob has worked extensively in technologies including antibodies, vaccines, chimeric antigen receptors, cell therapies, synthetic biology, medical devices, imaging agents, biologics, and small molecules for new disease indications.
Before beginning his career in the law, Rob was a neuroscientist engaged in drug discovery at Eli Lilly and Company.
Experience
- Implementing and executing global exclusivity strategies for polypeptide, antibody, and cell therapies for multinational pharmaceutical companies.
- Building of worldwide patent portfolio for repurposed small molecule.
- Responding to government agency investigations regarding Bayh-Dole compliance.
- Conducting IP diligence of biotech companies for acquisition or investment.
Activities
- American Intellectual Property Law Association
- Boston Intellectual Property Law Association
- Life Sciences Law360 Editorial Advisory Board
- Massbio MassCONNECT mentor
Recognition
- Repeatedly recognized in the IAM Patent 1000: The World’s Leading Patent Professionals
- Named to Boston Magazine’s Top Lawyers list